Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DR49KB
|
|||
| Drug Name |
CSL312
|
|||
| Synonyms |
Garadacimab
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Hereditary angioedema [ICD-11: 4A00.14; ICD-9: 277.6] | Phase 3 | [1] | |
| Company |
CSL Behring
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Coagulation factor XII (F12) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04656418) CSL312 (Garadacimab) in the Prevention of Hereditary Angioedema Attacks. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of CSL Behring. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.